Get weekly updates on this stock
MR The YouTuber identifies Merck & Co. as the 'safest stock in the stock market' due to its extremely low beta of 0.38, indicating minimal volatility…
The analyst suggests looking at Merck for those worried about further market losses, as the healthcare sector has held up and produced positive returns. This is presented as a safe haven stock.
The analyst suggests looking at Merck for those worried about further market losses, as the healthcare sector has held up and produced positive returns. This is presented as a safe haven stock.
“So, if you're worried about those further losses, look to names like Expand Energy, ticker EXE, Chevron, CVX, Merc, MRK, and Medronic, ticker MDT.”
The YouTuber suggests Merck as a value play in the healthcare sector, noting it's down 39% over the last year but now trading at a steep discount of 3.1 times sales compared to its historical 4-5x multiple. He believes the sector is in deep value territory and will be less volatile if the market dips.
“Even drug heavyweight Mark took her MRK is down 39% over the last year, but now trading at just 3.1 times sales, a steep discount to that four or 5x multiple it's traded at in the past.”
The analyst identifies Merck as a favorite within the healthcare sector, which is expected to post the highest earnings growth for the first quarter. The pharmaceuticals industry, in particular, is projected to have blowout earnings.
“favorites in the group include MC ticker MRK Eli Lily LL Johnson and Johnson ticker J&J and ABY ticker abbv”
The YouTuber identifies Merck & Co. as the 'safest stock in the stock market' due to its extremely low beta of 0.38, indicating minimal volatility compared to the market. This stability, combined with a dividend, makes it an attractive option for safer returns.
“and the safest stock in the stock market Merk and Company took her MRK with a beta of just 38 nearly a third the volatility on the market index”
The analyst favors Merck due to its stronger sales growth, higher profitability, and lower valuation compared to Johnson & Johnson. However, he cautions investors to monitor its increasing debt levels, as the company plans to be active in acquisitions to fill potential sales gaps from upcoming patent expirations for key drugs like Januvia and Keytruda.
“But looking at the fundamentals here for Merck a stronger sales growth stronger profitability lower PR lower valuation I think Merck has the advantage here if it can get over this patent Cliff.”
The analyst recommends avoiding Merck due to its projected underperformance compared to the market, with an estimated 8% annualized return over 10 years. He highlights concerns about flat revenue and EBITDA growth, a high dividend payout relative to free cash flow, and increasing debt to maintain the dividend, suggesting management is not making optimal capital allocation decisions for growth.
The analyst recommends avoiding Merck due to its projected underperformance compared to the market, with an estimated 8% annualized return over 10 years. He highlights concerns about flat revenue and EBITDA growth, a high dividend payout relative to free cash flow, and increasing debt to maintain the dividend, suggesting management is not making optimal capital allocation decisions for growth.
“I think it's one or two drugs dominate the portfolio so it's focused, I see a business that's married to paying a very large dividend relative to the cash it generates and as a result I've had to pay the cash dividend, it is borrowing money and the earnings are flat.”
A named stock, a clear buy or sell stance, and real reasoning. Passing mentions and hype are filtered out.
Each channel counts once per stock, so a single loud voice can't skew the ranking.
We weigh how many creators agree, how convinced they are, and how recent each call is.
2 finance YouTubers analysed Merck & Co with qualified reasoning — consensus: Buy, average analysis quality 75/100. This is not financial advice; review the individual analyses and sources above.
Among the channels covering Merck & Co, 1 are buying and 1 are selling or avoiding — overall Buy.
Only qualified analyses count: a clear buy/sell stance on Merck & Co with real reasoning (valuation, fundamentals, a catalyst or a chart setup). Passing mentions are excluded.